Abstract
Optimism regarding precision medicine has increased in recent years, and type 2 diabetes provides one of its more promising applications.1 The large public health burden of type 2 diabetes is exacerbated by inadequate treatments, which might be better designed or deployed if the complex and heterogeneous nature of type 2 diabetes could be refined into a collection of more homogeneous disease subtypes. Whether it is possible to treat type 2 diseases as a group of distinct qualitative subtypes,2 or whether type 2 diabetes progression and treatment responses are best modeled through continuous variables,3 remains debated—the reality is probably somewhere in between.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
